- Home
- NLSP vs ABEO Comparison
NLSP vs ABEO Comparison
Compare NLSP & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- ABEO
- Stock Information
- Founded
- NLSP 2015
- ABEO 1974
- Country
- NLSP Switzerland
- ABEO United States
- Employees
- NLSP N/A
- ABEO N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- ABEO Health Care
- Exchange
- NLSP Nasdaq
- ABEO Nasdaq
- Market Cap
- NLSP 12.4M
- ABEO 350.2M
- IPO Year
- NLSP 2021
- ABEO 1980
- Fundamental
- Price
- NLSP $2.09
- ABEO $5.60
- Analyst Decision
- NLSP
- ABEO Strong Buy
- Analyst Count
- NLSP 0
- ABEO 6
- Target Price
- NLSP N/A
- ABEO $18.17
- AVG Volume (30 Days)
- NLSP 193.8K
- ABEO 714.3K
- Earning Date
- NLSP 10-17-2025
- ABEO 11-13-2025
- Dividend Yield
- NLSP N/A
- ABEO N/A
- EPS Growth
- NLSP N/A
- ABEO N/A
- EPS
- NLSP N/A
- ABEO 0.99
- Revenue
- NLSP N/A
- ABEO $400,000.00
- Revenue This Year
- NLSP N/A
- ABEO N/A
- Revenue Next Year
- NLSP N/A
- ABEO $324.71
- P/E Ratio
- NLSP N/A
- ABEO $5.80
- Revenue Growth
- NLSP N/A
- ABEO N/A
- 52 Week Low
- NLSP $1.30
- ABEO $3.93
- 52 Week High
- NLSP $6.97
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- NLSP 44.87
- ABEO 47.60
- Support Level
- NLSP $1.88
- ABEO N/A
- Resistance Level
- NLSP $2.29
- ABEO $6.95
- Average True Range (ATR)
- NLSP 0.12
- ABEO 0.24
- MACD
- NLSP -0.01
- ABEO -0.36
- Stochastic Oscillator
- NLSP 43.90
- ABEO 78.39
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.